Equities Analysts Set Expectations for ORIC FY2025 Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of ORIC Pharmaceuticals in a report issued on Thursday, May 29th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings per share of ($1.71) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for ORIC Pharmaceuticals' current full-year earnings is ($2.17) per share.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09.

A number of other analysts have also issued reports on the company. Guggenheim reissued a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. HC Wainwright restated a "buy" rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Monday, May 5th. JPMorgan Chase & Co. raised their price objective on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Oppenheimer cut their price objective on ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Finally, Wedbush restated an "outperform" rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a report on Thursday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $19.17.

ORIC Pharmaceuticals Price Performance

NASDAQ:ORIC traded up $0.30 during mid-day trading on Monday, reaching $8.47. The company's stock had a trading volume of 3,128,825 shares, compared to its average volume of 744,671. The company's fifty day simple moving average is $5.43 and its two-hundred day simple moving average is $7.68. ORIC Pharmaceuticals has a twelve month low of $3.90 and a twelve month high of $14.67. The stock has a market cap of $602.12 million, a P/E ratio of -4.65 and a beta of 1.37.

Institutional Investors Weigh In On ORIC Pharmaceuticals

Several hedge funds have recently modified their holdings of ORIC. KLP Kapitalforvaltning AS purchased a new stake in shares of ORIC Pharmaceuticals during the 4th quarter valued at about $50,000. Arizona State Retirement System purchased a new stake in shares of ORIC Pharmaceuticals during the 1st quarter valued at about $56,000. BNP Paribas Financial Markets purchased a new stake in ORIC Pharmaceuticals during the 4th quarter worth approximately $71,000. Hsbc Holdings PLC purchased a new stake in ORIC Pharmaceuticals during the 1st quarter worth approximately $102,000. Finally, PNC Financial Services Group Inc. increased its holdings in ORIC Pharmaceuticals by 22.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock worth $109,000 after purchasing an additional 2,520 shares during the last quarter. 95.05% of the stock is currently owned by hedge funds and other institutional investors.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.